{"id":27744,"date":"2017-09-06T07:04:55","date_gmt":"2017-09-06T05:04:55","guid":{"rendered":"http:\/\/cms.munich-startup.net\/?p=27744"},"modified":"2017-09-05T15:46:07","modified_gmt":"2017-09-05T13:46:07","slug":"immunic-completes-financing-round","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/27744\/immunic-completes-financing-round\/","title":{"rendered":"Immunic completes financing round totaling 31.7 million euros"},"content":{"rendered":"<div class=\"entry-content\"><p><strong>Immunic AG (Immunic Therapeutics), a young biotechnology company based in Martinsried near Munich, has closed its Series A financing round with a total equity volume of \u20ac31.7 million. Omega Funds (Boston, MA, USA) and Fund+ (Leuven, Belgium) are participating with a total investment of \u20ac10 million. <a href=\"\/en\/19730\/immunic-erweitert-investitionsrunde-um-vier-millionen-euro\/\" target=\"_blank\">the existing international investor consortium<\/a>, led by Dutch VC investor LSP.<\/strong><\/p>\n<p>The <a href=\"http:\/\/www.immunic-therapeutics.com\/\" target=\"_blank\">Immunic AG<\/a> was founded in April 2016 with the goal of developing promising pharmaceutical projects through to clinical proof of concept. The company has two ongoing drug development programs. Both products target chronic inflammatory and autoimmune diseases, such as ulcerative colitis, Crohn&#039;s disease, and psoriasis.<\/p>\n<h3>Drug development is accelerated<\/h3>\n<p>The additional funding will be used for the rapid further development of these drugs. The project is currently in an advanced Phase I clinical trial. The start of Phase II clinical trials in patients with ulcerative colitis is planned for early 2018.<\/p>\n<blockquote><p>\u201cWe are extremely pleased that two such renowned, internationally operating life science investment funds have joined our investor group and added a further 10 million euros to our Series A,\u201d<\/p><\/blockquote>\n<p>says<strong> Dr. Daniel Vitt<\/strong>, Immunic&#039;s CEO and Chairman of the Board.<\/p>\n<blockquote><p>&quot;This step will significantly accelerate the further Phase II development of IMU-838 in the field of inflammatory bowel diseases. This investment strengthens our investor base and underscores our international visibility to US investors.&quot;<\/p><\/blockquote>\n<p><strong>Dr. J\u00f6rg Neermann<\/strong>, Partner at LSP and Chairman of the Supervisory Board of Immunic AG, welcomes Omega and Fund+ as new investors and shareholders:<\/p>\n<blockquote><p>&quot;We are very pleased that Omega and Fund+, two renowned international investors, are expanding our syndicate and thus contributing to Immunic&#039;s continued success. With Vincent Ossipow and Jan Van den Bossche, we welcome two experienced life science experts to Immunic&#039;s Supervisory Board.&quot;<\/p><\/blockquote>\n<h3>\u201cWe are overjoyed\u201d<\/h3>\n<p><strong>Dr. Vincent Ossipow<\/strong>, CFA and partner of Omega Funds, explains:<\/p>\n<blockquote><p>&quot;We believe IMU-838 has the potential to become the best DHODH inhibitor, and that this class of drugs will continue to grow in importance in the future. We are equally impressed by Immunic&#039;s ROR\u03b3t development program, and are therefore proud to be involved in this innovative company.&quot;<\/p><\/blockquote>\n<p>Dr. Ossipow will join the Supervisory Board of Immunic AG.<\/p>\n<blockquote><p>\u201cWe are delighted to now be part of this strong consortium of leading life science investors,\u201d<\/p><\/blockquote>\n<p>says <strong>Jan Van den Bossche<\/strong>, Partner of Fund+ and designated member of the Supervisory Board of Immunic AG.<\/p>\n<blockquote><p>&quot;We are extremely impressed by Immunic&#039;s experienced management team combined with highly innovative research. This powerful combination will ensure that significantly better treatment options for chronic inflammatory diseases will be available in the future.&quot;<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Immunic AG (Immunic Therapeutics), a young biotechnology company based in Martinsried near Munich, has completed its Series A financing round with a total equity volume of \u20ac31.7 million. Omega Funds (Boston, MA, USA) and Fund+ (Leuven, Belgium) have joined the existing international investor consortium, led by...<\/p>","protected":false},"author":3,"featured_media":27748,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5633,10,1],"tags":[52,2294],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.1.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro - Munich Startup<\/title>\n<meta name=\"description\" content=\"Die Immunic AG aus Martinsried hat ihre Series A Finanzierungsrunde in H\u00f6he von 31,7 Millionen Euro mit zwei weiteren Investoren komplettiert,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/27744\/immunic-completes-financing-round\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Die Immunic AG aus Martinsried hat ihre Series A Finanzierungsrunde in H\u00f6he von 31,7 Millionen Euro mit zwei weiteren Investoren komplettiert,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/27744\/immunic-completes-financing-round\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:author\" content=\"https:\/\/www.facebook.com\/profile.php?id=100009572160192\" \/>\n<meta property=\"article:published_time\" content=\"2017-09-06T05:04:55+00:00\" \/>\n<meta name=\"author\" content=\"Florian Deglmann\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@FlorianDeglmann\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Florian Deglmann\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/\",\"url\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/\",\"name\":\"Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg\",\"datePublished\":\"2017-09-06T05:04:55+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251\"},\"description\":\"Die Immunic AG aus Martinsried hat ihre Series A Finanzierungsrunde in H\u00f6he von 31,7 Millionen Euro mit zwei weiteren Investoren komplettiert,\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg\",\"width\":1280,\"height\":853,\"caption\":\"Immunic Biovaria\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251\",\"name\":\"Florian Deglmann\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g\",\"caption\":\"Florian Deglmann\"},\"description\":\"Der Exil-N\u00fcrnberger erforschte bis April 2019 als Redakteur die M\u00fcnchner Startup-Szene.\",\"sameAs\":[\"http:\/\/cms.munich-startup.net\",\"https:\/\/www.facebook.com\/profile.php?id=100009572160192\",\"https:\/\/x.com\/FlorianDeglmann\"],\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/deglmann\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immunic completes financing round totaling 31.7 million euros - Munich Startup","description":"Immunic AG from Martinsried has completed its Series A financing round of 31.7 million euros with two additional investors,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/27744\/immunic-completes-financing-round\/","og_locale":"en_US","og_type":"article","og_title":"Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro - Munich Startup","og_description":"Die Immunic AG aus Martinsried hat ihre Series A Finanzierungsrunde in H\u00f6he von 31,7 Millionen Euro mit zwei weiteren Investoren komplettiert,","og_url":"https:\/\/cms.munich-startup.net\/en\/27744\/immunic-completes-financing-round\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_author":"https:\/\/www.facebook.com\/profile.php?id=100009572160192","article_published_time":"2017-09-06T05:04:55+00:00","author":"Florian Deglmann","twitter_card":"summary_large_image","twitter_creator":"@FlorianDeglmann","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Florian Deglmann","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/","url":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/","name":"Immunic completes financing round totaling 31.7 million euros - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg","datePublished":"2017-09-06T05:04:55+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251"},"description":"Immunic AG from Martinsried has completed its Series A financing round of 31.7 million euros with two additional investors,","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg","width":1280,"height":853,"caption":"Immunic Biovaria"},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/27744\/immunic-komplettiert-finanzierungsrunde\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Immunic komplettiert Finanzierungsrunde von insgesamt 31,7 Millionen Euro"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/2371b77bb47cd783e9e1f88e88d9f251","name":"Florian Deglmann","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/1e3087740aeaedbec23f0c7300f1beeb?s=96&d=blank&r=g","caption":"Florian Deglmann"},"description":"The exiled Nuremberg resident researched the Munich startup scene as an editor until April 2019.","sameAs":["http:\/\/cms.munich-startup.net","https:\/\/www.facebook.com\/profile.php?id=100009572160192","https:\/\/x.com\/FlorianDeglmann"],"url":"https:\/\/cms.munich-startup.net\/en\/author\/deglmann\/"}]},"og_image":[{"width":1280,"height":853,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/09\/medic-563425_1280.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1645629593:38","_edit_last":"24","_yoast_wpseo_focuskw":"Immunic","_yoast_wpseo_metadesc":"Die Immunic AG aus Martinsried hat ihre Series A Finanzierungsrunde in H\u00f6he von 31,7 Millionen Euro mit zwei weiteren Investoren komplettiert,","_yoast_wpseo_linkdex":"82","_thumbnail_id":"27748","wbounce_status":"default","_yoast_wpseo_primary_category":"5633","_yoast_wpseo_focuskw_text_input":"Immunic","_yoast_wpseo_content_score":"60","ms_image_format":"","_ms_image_format":"","ms_dachzeile":"","_ms_dachzeile":"","ms_bump_post_date":"","_ms_bump_post_date":"","guest_author_name":"","_guest_author_name":"","guest_author_image":"","_guest_author_image":"","guest_author_description":"","_guest_author_description":"","ms_post_image_caption":"","_ms_post_image_caption":"","ms_post_image_credit":"","_ms_post_image_credit":"","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/27744"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=27744"}],"version-history":[{"count":0,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/27744\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/27748"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=27744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=27744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=27744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}